retatrutide phase 2 trial obesity nejm 2023 2023年度回顧】 Notable Articles of Day 3: Triple–Hormone-Receptor Agonist for — A Trial. N Engl J Med 2023; 389:514-526. 製圖：Sardinosis Phase 2 Trial of Retatrutide
Description
Your body still needs care
That matters for surgery and procedures
These patterns rarely mean a lack of willpower
They act on receptors in the brain to influence and decrease eating behavior
Integrate GLP-1 coverage with robust, wraparound support, such as condition management programs, nutrition counseling, and wellness coaching
It also has antiemetic properties that reduce the nausea-related air swallowing that contributes to burping
